Hosted on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...
Benzinga.com

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms ...
The Indianapolis Star

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus ® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus ® Recent financings ...
Seeking Alpha

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

n = number of patients included in each study group for safety and tolerability assessments Abbreviations: EOS: End of Study (week 16); BID: twice daily; CBD: cannabidiol; QD: once daily. Of the DHT ...
Seeking Alpha

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

n = number of patients included in each study group for HbA1c and body weight efficacy assessments Abbreviations: EOS: End of Study (week 16); Wk: week; BID: twice daily; CBD: cannabidiol; QD: once ...